Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.

Eustace AJ, Dowling P, Henry M, Doolan P, Meleady P, Clynes M, Crown J, O'Donovan N.

J Proteomics. 2011 Apr 1;74(4):490-501. doi: 10.1016/j.jprot.2010.12.011. Epub 2011 Jan 13.

PMID:
21237296
2.

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N.

J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53.

3.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

4.

Phosphosignature predicts dasatinib response in non-small cell lung cancer.

Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, Müller S, Tebbe A, Godl K, Schaab C.

Mol Cell Proteomics. 2012 Sep;11(9):651-68. doi: 10.1074/mcp.M111.016410. Epub 2012 May 21.

5.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

6.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

7.

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27.

PMID:
18301894
8.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
9.

HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.

deBlacam C, Byrne C, Hughes E, McIlroy M, Bane F, Hill AD, Young LS.

Br J Cancer. 2011 Jun 28;105(1):118-23. doi: 10.1038/bjc.2011.193. Epub 2011 Jun 7.

10.

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.

Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27.

11.

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Lu H, Wang L, Gao W, Meng J, Dai B, Wu S, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B.

Mol Cancer Ther. 2013 Dec;12(12):2864-73. doi: 10.1158/1535-7163.MCT-13-0233. Epub 2013 Oct 15.

12.

Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.

Vitali R, Mancini C, Cesi V, Tanno B, Piscitelli M, Mancuso M, Sesti F, Pasquali E, Calabretta B, Dominici C, Raschellà G.

Int J Cancer. 2009 Dec 1;125(11):2547-55. doi: 10.1002/ijc.24606.

13.
14.

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.

Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):531-8. doi: 10.1016/j.jtcvs.2012.10.041. Epub 2012 Nov 9.

15.

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.

Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, Diener KR, Hayball JD.

Cancer Biol Ther. 2010 Oct 1;10(7):715-27. Epub 2010 Oct 1.

PMID:
20676039
16.

An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.

Xing H, Liu T, Meng W, Gong Y.

Int J Lab Hematol. 2011 Apr;33(2):176-81. doi: 10.1111/j.1751-553X.2010.01267.x. Epub 2010 Oct 4.

PMID:
20942869
17.

Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.

Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K.

Mol Cancer Ther. 2010 May;9(5):1188-97. doi: 10.1158/1535-7163.MCT-10-0002. Epub 2010 Apr 20.

18.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

19.

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR.

Int J Cancer. 2007 Jul 15;121(2):257-64.

20.

Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.

Shi M, Lou B, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J.

Cancer Chemother Pharmacol. 2013 Jul;72(1):35-44. doi: 10.1007/s00280-013-2166-1. Epub 2013 May 28.

PMID:
23712327

Supplemental Content

Support Center